Mold-Tek Packaging (533080) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
9 Sep, 2026Executive summary
Achieved 7.5% year-over-year and 9.07% sequential volume growth in Q1 FY25, with EBITDA up 2.77% YoY and 2.5% QoQ, though per kg EBITDA declined due to capitalization of costs ending as new plants commenced production.
Net sales increased by 11.22% quarter-on-quarter (Q1 FY25 vs Q4 FY24), reaching ₹196.72 crores.
Three new plants (Cheyyar, Panipat for ABG, and Sultanpur for pharma) are now operational, but currently running at 15%-25% utilization, expected to ramp up in coming quarters.
Commercial supplies to Grasim Industries (Aditya Birla Group) and pharma packaging unit began, with audits completed for ISO and DMF certifications.
EBITDA rose by 2.46% quarter-on-quarter to ₹36.67 crores, but profit before tax declined by 6% and net profit dropped by 8% sequentially due to higher depreciation and finance costs.
Financial highlights
Q1 revenue: INR 196.5 crores; Paints: INR 83.5 crores, Lubes: INR 46.7 crores, Food: INR 41.6 crores, Qpack: INR 23.8 crores, Pharma: INR 0.8 crores.
Q1 volumes: Paints 4,605 tons, Lubes 2,574 tons, Food & FMCG 1,365 tons, Qpack 1,331 tons, Pharma 19 tons.
EBITDA for Q1 FY25: ₹36.67 crores, up 2.46% from Q4 FY24 and 2.77% year-over-year.
Profit before tax for Q1 FY25: ₹22.19 crores, down 6% from Q4 FY24 and 10.4% year-over-year.
Net profit for Q1 FY25: ₹16.53 crores, down 8% from Q4 FY24 and 11.76% year-over-year.
Outlook and guidance
Maintains mid-teen (15%) volume growth guidance for FY25, despite Q1 growth of 7.5%, requiring 17%-18% growth in the remaining quarters.
Pharma segment expected to contribute INR 15-20 crores in FY25, with significant ramp-up from Q3 onwards and higher EBITDA margins (INR 100-150 per kg depending on product mix).
Targeting INR 1,000 crores topline and INR 100 crores PAT by FY26, driven by pharma and ABG ramp-up.
Capacity expansion underway at Grasim Industries plants to support anticipated future growth.
Commercial supplies in pharma packaging expected to ramp up from October 2024, with new product developments in progress.
Latest events from Mold-Tek Packaging
- Sales and EBITDA rose, but net profit fell due to higher costs; capacity expansions underway.533080
Q2 24/25 - Q3 FY25 saw strong revenue and EBITDA growth, but PAT fell on higher costs; pharma and exports are rising.533080
Q3 24/25 - Revenue and EBITDA rose, but net profit declined as costs increased; pharma and FMCG led growth.533080
Q4 24/25 - Q1FY26 saw 22% revenue growth and 35.5% profit rise, led by pharma and FMCG momentum.533080
Q1 25/26 - H1FY26 revenue up 16.05% and PAT up 24%, led by strong pharma and FMCG growth.533080
Q2 25/26 - EBITDA and PAT up nearly 20% YoY, led by pharma and FMCG growth, with strong outlook.533080
Q3 25/26 - EBITDA and PAT grew over 20% YoY, with robust Pharma and FMCG segment growth and strong FY27 outlook.533080
Q4 25/26 - Record revenue and profit growth led by pharma, food, and FMCG, with historic EBITDA per kg.533080
Q1 26/27